Biotech IT & AI consultingScience, and the speed to believable evidence.
Biotech lives or dies on the science and on how fast the company can turn it into evidence investors and regulators will believe.
Primary shape of the AI dividend this year: Rising Bar.
A technology estate nobody planned.
Between the science and the evidence sits a technology estate most emerging companies never planned: an ELN here, instrument software there, results in shared drives and spreadsheets.
We bring fractional CIO leadership into life-science companies through Contract CIO+®, ongoing technology counsel through CIO IQ®, and guidance for scientific AI.
Biotech in 2026.
Recovery meeting reinvention.
On discriminating terms
Capital is returning, with more discriminating expectations of the data behind each program.
Investor-ready data
Results in shared drives and spreadsheets turned into evidence regulators and investors trust.
ELN and instruments
An integrated lab and data estate instead of scattered tools.
From slideware to bench
AI is moving into the lab and needs governed data to work.
Rising Bar
Primary shape of the AI dividend this year.
Our top-line approach.
Technology that keeps pace with the science.
Stabilize
Secure and organize data across instruments, notebooks, and drives.
Optimize
Integrate the lab stack so evidence flows faster.
Monetize
Put AI to work at the bench to speed discovery.
Talk with a life-science technology leader.
A former CIO, CTO, or CISO from the sector, vendor-neutral, with the only agenda yours.